Cannabidiol: a potential new alternative for the treatment of anxiety, depression, and psychotic disorders

MS García-Gutiérrez, F Navarrete, A Gasparyan… - Biomolecules, 2020 - mdpi.com
The potential therapeutic use of some Cannabis sativa plant compounds has been attracting
great interest, especially for managing neuropsychiatric disorders due to the relative lack of …

Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age

JA Crippa, FS Guimarães, AC Campos… - Frontiers in …, 2018 - frontiersin.org
Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a
compound that does not produce the typical subjective effects of marijuana. Objectives: The …

[HTML][HTML] Cannabidiol as a potential treatment for anxiety disorders

EM Blessing, MM Steenkamp, J Manzanares… - …, 2015 - Elsevier
Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum
drug that in recent years has drawn increasing interest as a treatment for a range of …

From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology

A Ligresti, L De Petrocellis… - Physiological …, 2016 - journals.physiology.org
Apart from having been used and misused for at least four millennia for, among others,
recreational and medicinal purposes, the cannabis plant and its most peculiar chemical …

The polypharmacological effects of cannabidiol

J Castillo-Arellano, A Canseco-Alba, SJ Cutler, F León - Molecules, 2023 - mdpi.com
Cannabidiol (CBD) is a major phytocannabinoid present in Cannabis sativa (Linneo, 1753).
This naturally occurring secondary metabolite does not induce intoxication or exhibit the …

Cannabidiol, neuroprotection and neuropsychiatric disorders

AC Campos, MV Fogaça, AB Sonego… - Pharmacological …, 2016 - Elsevier
Cannabidiol (CBD) is a non-psychotomimetic phytocannabinoid derived from Cannabis
sativa. It has possible therapeutic effects over a broad range of neuropsychiatric disorders …

Medial prefrontal cortex in neurological diseases

P Xu, A Chen, Y Li, X Xing, H Lu - Physiological genomics, 2019 - journals.physiology.org
The medial prefrontal cortex (mPFC) is a crucial cortical region that integrates information
from numerous cortical and subcortical areas and converges updated information to output …

Cannabidiol (CBD) use in psychiatric disorders: A systematic review

S Bonaccorso, A Ricciardi, C Zangani, S Chiappini… - Neurotoxicology, 2019 - Elsevier
Abstract Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) are the most represented
phytocannabinoids in Cannabis sativa plants. However, CBD may present with a different …

[HTML][HTML] Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life

AW Zuardi, NP Rodrigues, AL Silva… - Frontiers in …, 2017 - frontiersin.org
The purpose of this study was to investigate whether the anxiolytic effect of cannabidiol
(CBD) in humans follows the same pattern of an inverted U-shaped dose-effect curve …

Clinical and preclinical evidence for functional interactions of cannabidiol and Δ9-tetrahydrocannabinol

DL Boggs, JD Nguyen, D Morgenson… - …, 2018 - nature.com
The plant Cannabis sativa, commonly called cannabis or marijuana, has been used for its
psychotropic and mind-altering side effects for millennia. There has been growing attention …